BIOSIG TECHNOLOG. DL-,001 Logo
US09073N2018
A2N5TW
BSGM

BIOSIG TECHNOLOG. DL-,001

Previsión

El precio objetivo medio de los analistas es de 0,37 € (-92,24 %). La mediana es de 0,37 € (-92,24 %).

Comprar
  2
Mantener
  0
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • BioSig Technologies renamed Streamex Corp after merger and gets new ticker symbol STEX

    BioSig Technologies will change its name to Streamex Corp. effective September 12, 2025, following its merger with Streamex Exchange Corporation, and will change its Nasdaq ticker from BSGM to STEX; shareholders do not need to take any action and the CUSIP remains unchanged. The company completed a committed capital raise of about $15 million by selling 3,852,149 common shares at $3.90 per share and intends to use the net proceeds, among other things, to purchase gold bars and for working capital. Authorized common shares were increased from 200 million to 500 million, and through its subsidiary Streamex the company entered a three‑year exclusive partnership with Monetary Metals to tokenize yield‑bearing gold products. Apart from the rebranding, the structure and operating business are to remain unchanged. » Más en de.investing.com


  • Streamex teams up with Monetary Metals for tokenized gold product with up to 4% yield

    Streamex, a subsidiary of BioSig, obtained exclusive three-year rights to tokenize interest-bearing gold products from Monetary Metals and access to its leasing and bond programs. Investors could therefore earn annual returns of up to 4% on tokenized gold bar products; Streamex will finance at least 10% of the qualifying gold-leasing contracts and receive a revenue-linked share. BioSig also raised about USD 15 million through a public offering, will purchase gold bars and is using the capital increase, while InvestingPro points to weak financial metrics and short-term liquidity shortages. » Más en de.investing.com


  • BioSig Technologies: shareholders approve share increase and new board structure

    Shareholders of BioSig Technologies voted to increase the authorized common shares from 200 million to 500 million and approved an increase to the long-term incentive plan. They also approved measures to issue common shares and convertible debt in connection with Yorkville and the classification of the board of directors into three classes with staggered three-year terms. The vote on the issuance of about 109,070,079 common shares and one super-voting preferred share related to the Streamex acquisition was deferred pending Nasdaq approval; the meeting will resume on September 26. In addition, BioSig completed an underwritten offering of roughly $15 million and restructured convertible notes with YA II PN, Ltd. (two secured convertible notes of $25 million each, with the option to expand to $50 million). » Más en de.investing.com


  • Solana gains major boost as BioSig Technologies tokenizes $1.1 billion in gold on its blockchain

    BioSig Technologies will tokenize up to $1.1 billion in physical gold bullion on the Solana blockchain, significantly increasing Solana's real-world asset footprint. This move highlights Solana's technical strengths, such as low fees and high transaction speeds, and positions it as a leader in the growing asset tokenization trend. The development is seen as a strong validation of Solana's capabilities and a potential catalyst for further growth. » Más en finance.yahoo.com


  • BioSig Technologies expands Streamex advisory team with Russell Starr and secures growth financing

    BioSig Technologies has appointed Russell Starr as a strategic advisor for its subsidiary Streamex Exchange Corporation to advance the tokenization of gold reserves and infrastructure. The company also secured up to $1.1 billion in growth financing to support its gold-backed treasury strategy and expanded its advisory team with additional industry experts. Analysts view the stock positively due to the new strategy and potential market returns, despite the company's continued weak financial position. » Más en de.investing.com

Datos financieros

En el último trimestre, BIOSIG TECHNOLOG. DL-,001 tuvo unos ingresos de 0 € y un beneficio neto de -13,28 M €

(EUR) septiembre de 2025
YoY
Ingresos 0 -
Beneficio bruto 0 -
Beneficio neto -13,28 M -
EBITDA -12,66 M -

Datos fundamentales

Métrica Valor
Capitalización bursátil
174,19 M €
Número de acciones
31,33 M
Máximo/mínimo de 52 semanas
12,86 € - 0,21 €
Dividendos No
Beta
1,82
Ratio P/E
-0,03
Ratio PEG
0,00
Ratio P/B
0,42
Ratio P/S
121,85

Perfil de la empresa

BioSig Technologies, Inc., junto con sus subsidiarias, opera como empresa de dispositivos médicos. El producto patentado de la compañía incluye el sistema PURE EP (Precise Uninterrupted Real-time Evaluation of Electrograms Electrophysiology), una plataforma de procesamiento de señales que combina hardware y software para abordar los desafíos conocidos asociados a la adquisición de señales y que permite a los electrofisiólogos visualizar las señales y analizarlas en tiempo real. También se centra en mejorar la adquisición de señales intracardíacas y la información diagnóstica para los procedimientos de fibrilación auricular, y está diseñada para abordar las limitaciones de larga data que ralentizan e interrumpen los procedimientos de ablación cardíaca con catéter. La compañía tiene un acuerdo de investigación con la Universidad de Minnesota para desarrollar terapias novedosas para tratar enfermedades del sistema nervioso simpático; y una colaboración estratégica con la Mayo Foundation for Medical Education and Research para desarrollar una solución de software de IA y aprendizaje automático para los sistemas PURE EP. BioSig Technologies, Inc. se constituyó en 2009 y tiene su sede en Westport, Connecticut.

Nombre
BIOSIG TECHNOLOG. DL-,001
CEO
Anthony Amato
Sede Los Angeles, ct
Estados Unidos
Sitio web
Sector
Salud
Industria
Equipos y suministros sanitarios
Salida a bolsa
31/10/2014
Empleados 5

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
BSGM
🍪

Parqet  usa cookies. Más información